Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
This article was originally published in The Pink Sheet Daily
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
You may also be interested in...
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.
Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.